ABT - Abbott Laboratories
| Previous Close | 59.190 |
| Open | 59.280 |
| Bid | 59.290 x 700 |
| Ask | 59.300 x 400 |
| Day's Range | 59.010 - 59.460 |
| 52 Week Range | 42.880 - 64.600 |
| Volume | 1,358,765 |
| Avg. Volume | 7,297,148 |
| Market Cap | 103.479B |
| Beta | 1.67 |
| PE Ratio (TTM) | 220.28 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.12 (1.90%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks•4 hours ago
The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive
The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive
- Zacks•3 days ago
Top Analyst Reports for Goldman Sachs, Abbott & Altria
Top Analyst Reports for Goldman Sachs, Abbott & Altria
- Investor's Business Daily•4 days ago
Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves
Edwards Lifesciences, Medtronic, Boston Scientific and Abbott Laboratories are duking it out for a share of the fast-growing heart-valve replacement market.
- Investor's Business Daily•5 days ago
Abbott Shares Topple After Pharma Unit Struggles In First Quarter
Shares of Abbott Laboratories dipped early Wednesday — despite its broad first-quarter beat — on pharmaceutical sales that lagged Wall Street's expectations by nearly 4%.
Motley Fool•5 days agoAbbott Laboratories (ABT) Q1 2018 Earnings Conference Call Transcript
ABT earnings call for the period ending March 31, 2018.
- TheStreet.com•5 days ago
Dow Declines Slightly as S&P 500, Nasdaq Post Modest Gains
rose just 0.06% after posting a 38% increase in first-quarter profit. S&P 500 companies are expected to post an 18.6% increase in first-quarter profit, the biggest rise in seven years, according to Thomson Reuters.
- TheStreet.com•5 days ago
3 Hot Reads From TheStreet's Top Premium Columnists
Jim Cramer and our other experts look at banks, three sections to trade, and REITs.
- Simply Wall St.•5 days ago
Is Abbott Laboratories’s (NYSE:ABT) Balance Sheet Strong Enough To Weather A Storm?
The size of Abbott Laboratories (NYSE:ABT), a US$104.43B large-cap, often attracts investors seeking a reliable investment in the stock market. Doing business globally, large caps tend to have diversified revenueRead More...
Reuters•5 days agoAbbott sticks to earlier forecasts, disappoints investors
Some analysts also said a 6.9 percent rise in organic sales, which excludes the impact of foreign currency and certain divestitures and acquisitions, was just shy of a roughly 7 percent expected by investors. Thomson Reuters I/B/E/S had no consensus estimate for the organic sales.
- InvestorPlace•5 days ago
Abbott Laboratories Stock Slips Despite Earnings Beat
This is an increase over its earnings per share of 48 cents from the same time last year. It also beat out Wall Street’s earnings per share estimate of 58 cents for the period. Net income reported by Abbott Laboratories in the first quarter of 2018 came in at $418 million.
Reuters•5 days agoAbbott sticks to earlier forecasts, disappoints investors
Some analysts also said a 6.9 percent rise in organic sales, which excludes the impact of foreign currency and certain divestitures and acquisitions, was just shy of a roughly 7 percent expected by investors. Thomson Reuters I/B/E/S had no consensus estimate for the organic sales.
- TheStreet.com•5 days ago
Abbott CEO: New Glucose Device's U.S. Launch 'Has Gone Exceptionally Well'
continuous glucose monitoring system FreeStyle Libre is off to a strong start. The debut of Libre, which was approved for sale by the U.S. Food and Drug Administration last September, "has gone exceptionally well," said Abbott chairman and CEO Miles White on an earnings call on Wednesday, April 18. FreeStyle Libre, which was initially launched in Europe in 2014, already has a little over 50,000 users in the U.S., according to White.
- Zacks•5 days ago
Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained
Abbott (ABT) continues to gain from a strong and consistent EPD as well as a robust Medical Devices performance.
- Zacks•5 days ago
Abbott (ABT) Beats on Earnings and Revenues in Q1
Abbott (ABT) gains ground on new product launches and delivers strong Q1 results.
- TheStreet.com•5 days ago
Abbott Laboratories Tops Q1 Earnings Estimates, Issues Full Year Guidance
Abbott sees full year earnings of between $2.80 to $2.90 a share after a solid first quarter that topped Wall Street forecasts.
- MarketWatch•5 days ago
Abbott Labs beats profit and sales expectations, shares slip
Shares of Abbott Laboratories slipped 0.8% in premarket trade Wednesday, although the health care company reported first-quarter profit and sales that rose above expectations. Net income slipped to $418 ...
- Associated Press•5 days ago
Abbott: 1Q Earnings Snapshot
The Abbott Park, Illinois-based company said it had net income of 23 cents per share. Earnings, adjusted for one-time gains and costs, came to 59 cents per share. The results beat Wall Street expectations. ...
- Zacks•6 days ago
5 Amazing Earnings Charts This Week
It's not easy to beat the estimate nearly every quarter for years. But these 5 companies are doing it.
- Yahoo Finance•6 days ago
Amex, Morgan Stanley, Beige Book — What you need to know in markets on Wednesday
Stocks have rallied to start the week and brought the Dow back into the green for the year. Earnings from American Express and Morgan Stanley will be the key events for investors on Wednesday.
- TheStreet.com•6 days ago
Glucose Monitoring Device in Focus as Abbott Preps to Unveil Earnings
Abbott's Freestyle Libre in September secured FDA approval and in January, the company said the device had received reimbursement from the Centers for Medicare & Medicaid Services.
- Zacks•7 days ago
3 Stocks to Buy Ahead of Earnings
Stocks opened higher on Monday as investors seem to think the U.S.-led air strikes on Syria won't lead to a much larger conflict. The strikes also coincided with the real start of first quarter earnings season, which investors should use as a way to fight off the volatility that has plagued markets recently.
- Simply Wall St.•7 days ago
Is Abbott Laboratories (NYSE:ABT) Worth $58.49 Based On Intrinsic Value?
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Abbott Laboratories (NYSE:ABT) as an investment opportunity. If you wantRead More...
- Zacks•10 days ago
Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings?
Abbott (ABT) poised to gain on continued growth in Medical devices business in Q1.
- Zacks•12 days ago
Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?
Abbott (ABT) to see impressive year-over-year rise in revenues on strength in all business segments in Q1.
